An increasing number of epidemiologic, genetic, and genome‐wide association studies suggest that reducing plasma ANGPTL3 levels by inhibiting hepatic ANGPTL3 synthesis will benefit apolipoprotein B levels and improve the metabolic measurements related to dyslipidemia and atherosclerosis.72 This evidence concerns the gene ANGPTL3 and metabolic syndrome.